MOGAT: A phase 2 trial of mogamulizumab in cutaneous T-cell lymphoma

This trial is testing an innovative treatment schedule where mogamulizumab is used before Total Skin Electron Beam Therapy (TSEB) and then as a maintenance treatment in people with cutaneous T-cell lymphoma (CTCL). 

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT04128072
 

Trial aim and background  

The aim of this trial is to study the effectiveness and treatment side effects of mogamulizumab when it is given before TSEB for systemic disease control, and then as a maintenance treatment once TSEB has finished in people with CTCL.

CTCL has a chronic relapsing course where patient’s often need to often have multiple treatments. Treatment aims to clear the skin disease, reduce the risk of recurrence, prevent progression and improve quality of life. 

Currently there is no standard treatment option for CTCL and the sequence of treatments varies from hospital to hospital. This study will be looking at mogamulizumab given before TSEB for treatment of systemic disease and then as a maintenance treatment after. The hope is that this will lead to less side effects.

Who can enter

People aged over 18 with stage 1-3 CTCL who have failed at least one prior course of systemic therapy (refractory disease) or who have relapsed may be eligible for this trial.

Locations

Recruitment is taking place at The Christie NHS Foundation Trust, Manchester

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/ct2/show/NCT04128072

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.